Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06290128 · ClinicalTrials.gov registry record · Phase 3
A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not Work
A Phase 3 study of Chronic Inflammatory Demyelinating Polyradiculoneuropathy and Polyneuropathy, Inflammatory Demyelinating, Chronic, sponsored by Sanofi.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 140
- Enrollment target
- 20
- Study locations
NCT06290128: Recruiting Phase 3 study of Chronic Inflammatory Demyelinating Polyradiculoneuropathy and Polyneuropathy, Inflammatory Demyelinating, Chronic, sponsored by Sanofi.
NCT06290128 is a Phase 3 study of Chronic Inflammatory Demyelinating Polyradiculoneuropathy and Polyneuropathy, Inflammatory Demyelinating, Chronic that is actively recruiting participants, run by Sanofi. The registered enrollment target is 140 participants, above the 116-participant average among 4 other Chronic Inflammatory Demyelinating Polyradiculoneuropathy trials with a reported enrollment target (21% higher). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06290128, a Phase 3 study of Chronic Inflammatory Demyelinating Polyradiculoneuropathy and Polyneuropathy, Inflammatory Demyelinating, Chronic, is actively recruiting participants, sponsored by Sanofi.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 140 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of the study is to evaluate efficacy of riliprubart compared to placebo in adult participants with CIDP whose disease is refractory to standard of care. The study duration will be for a maximum of 111 weeks including screening, treatment phases, and follow-up.
Primary Outcome
A response is defined as a decrease of ≥1 point from baseline in adjusted INCAT disability score at Week 24.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Riliprubart
Study Locations (20)
California
- USC Norris Comprehensive Cancer Center- Site Number : 8400002 - Los Angeles
- University of California Irvine - Manchester Pavilion- Site Number : 8400007 - Orange
Louisiana
- NeuroMedical Clinic of Central Louisiana- Site Number : 8400031 - Alexandria
- Ochsner Medical Center - Jefferson Highway- Site Number : 8400030 - New Orleans
Michigan
- Henry Ford Hospital- Site Number : 8400025 - Detroit
- Michigan State University- Site Number : 8400038 - East Lansing
New York
- Hospital for Special Surgery- Site Number : 8400041 - New York
- Columbia University Irving Medical Center- Site Number : 8400003 - New York
Ohio
- University of Cincinnati Medical Center- Site Number : 8400020 - Cincinnati
- University Hospitals Cleveland Medical Center- Site Number : 8400033 - Cleveland
Pennsylvania
- Penn State Health Milton South Hershey Medical Center- Site Number : 8400042 - Hershey
- Penn Medicine: University of Pennsylvania Health System- Site Number : 8400022 - Philadelphia
Alabama
- Alabama Neurology Associates- Site Number : 8400019 - Homewood
Connecticut
- Yale University School of Medicine- Site Number : 8400018 - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2024-07-12 |
| Est. Completion | 2028-11-20 |
| Phase | Phase 3 |
What NCT06290128 shows while recruiting
NCT06290128 is an interventional study that assigns participants to a tested intervention. The registered 140 participants enrollment target is mid-sized for trials with a published cap, above the 116-participant average among 4 other Chronic Inflammatory Demyelinating Polyradiculoneuropathy trials with a reported enrollment target (21% higher).
The record links to 2 conditions, with Chronic Inflammatory Demyelinating Polyradiculoneuropathy appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06290128 names 20 study sites across 14 states, led by California, Louisiana, Michigan.
Frequently Asked Questions
What is clinical trial NCT06290128 about?
NCT06290128 is a clinical study titled "A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not Work". The purpose of the study is to evaluate efficacy of riliprubart compared to placebo in adult participants with CIDP whose disease is refractory to standard of care. The study duration will be for a maximum of 111 weeks including screening, treatment phases, and follow-up.
What is the current status of trial NCT06290128?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 140 participants. The study started on 2024-07-12. Estimated completion is 2028-11-20.
What conditions does trial NCT06290128 study?
This clinical trial studies the following conditions: Chronic Inflammatory Demyelinating Polyradiculoneuropathy, Polyneuropathy, Inflammatory Demyelinating, Chronic.
What interventions are being tested in trial NCT06290128?
The interventions under investigation include: Placebo (DRUG), Riliprubart (DRUG).
Who is sponsoring clinical trial NCT06290128?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06290128 being conducted?
This trial has 20 study locations across Alabama, California, Connecticut, Illinois, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP
RECRUITING · Phase 3
-
Long-Term Tolerability and Safety of HYQVIA/HyQvia in CIDP
COMPLETED · Phase 3
-
Real-World Efgartigimod Effectiveness in CIDP: A Prospective Study
RECRUITING
-
Clinical Trial to Assess the Safety of a Novel Scaffold Biomaterial
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01419561 · 140 participants · Phase 2
Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS)
- NCT01624805 · 140 participants · Phase 2
Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome
- NCT02369770 · 140 participants · NA
Sensory-Motor Rehabilitation Post Stroke
- NCT02455193 · 140 participants · NA
Neuronal Effects of Exercise in Schizophrenia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI